News | December 28, 2021
CDSCO expert committee recommends Emergency Use Authorisation to Covovax and Corbevax
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
The product is expected to be available in a week’s time
It plans to deliver over 300 million doses to the Indian government
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Subscribe To Our Newsletter & Stay Updated
